Table 3.
Diagnosis | Clinically useful | Nondiagnostic | Incorrect | Repeat biopsy | Total |
---|---|---|---|---|---|
Giant cell tumor | 27 (96%) | 1 (4%) | 0 (0%) | 2 (8%) | 28 |
Lymphoma | 20 (77%) | 5 (19%) | 1 (4%) | 10 (38%) | 26 |
Liposarcoma | 15 (83%) | 1 (6%) | 2 (11%) | 2 (11%) | 18 |
Myeloma | 16 (94%) | 1 (6%) | 0 (0%) | 3 (18%) | 17 |
Osteosarcoma | 13 (81%) | 1 (6%) | 2 (13%) | 3 (19%) | 16 |
Pigmented villonodular synovitis | 14 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 |
Myxoma | 13 (93%) | 1 (7%) | 0 (0%) | 1 (7%) | 14 |
Lung metastasis | 13 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 |
Schwannoma | 12 (92%) | 1 (8%) | 0 (0%) | 1 (8%) | 13 |
Lipoma (atypical, spindle cell) | 12 (100%) | 0 (0%) | 0 (0%) | 1 (8%) | 12 |
Chondrosarcoma | 10 (91%) | 1 (9%) | 0 (0%) | 2 (18%) | 11 |
Aneurysmal bone cyst | 9 (89%) | 2 (11%) | 0 (0%) | 4 (33%) | 11 |
Undifferentiated pleomorphic sarcoma (soft tissue) | 9 (82%) | 2 (18%) | 0 (0%) | 3 (25%) | 11 |
Osteomyelitis* | 8 (73%) | 3 (27%) | 0 (0%) | 3 (27%) | 11 |
Renal metastasis | 7 (78%) | 1 (11%) | 1 (11%) | 2 (22%) | 9 |
Fibromyxoid sarcoma | 5 (62%) | 0 (0%) | 3 (38%) | 1 (13%) | 8 |
Histiocytosis | 4 (50%) | 4 (50%) | 0 (0%) | 3 (38%) | 8 |
Ganglion cyst | 7 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 |
Breast metastasis | 6 (86%) | 1 (14%) | 0 (0%) | 1 (14%) | 7 |
Ewing sarcoma | 6 (86%) | 1 (14%) | 0 (0%) | 1 (14%) | 7 |
Desmoid tumor | 6 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 |
Stress fracture | 5 (83%) | 1 (17%) | 0 (0%) | 1 (17%) | 6 |
Prostate metastasis | 4 (67%) | 2 (33%) | 0 (0%) | 2 (33%) | 6 |
Hemangioma | 4 (80%) | 1 (20%) | 0 (0%) | 1 (20%) | 5 |
Hemangioendothelioma (bone) | 3 (60%) | 2 (40%) | 0 (0%) | 2 (40%) | 5 |
* Only two patients with osteomyelitis had positive microbiologic results on needle biopsy despite none previously having taken antibiotics; diagnoses not listed with sample size less than five patients owing to limitations of statistical testing (most diagnoses with fewer than five patients were nonneoplastic lesions).